We read with interest the article by Lowder et al1 on the outcomes of the dexamethasone intravitreal implant for treatment of noninfectious intermediate or posterior uveitis. Lowder et al1 found that the implant was able to significantly reduce intraocular inflammation and improve visual acuity for 6 months in patients with uveitis. Also, fewer than 5% of eyes developed an intraocular pressure (IOP) of 35 mm Hg or greater, and fewer than 10% of eyes developed an IOP of 25 mm Hg or greater. Approximately one-quarter of patients required topical antihypertensive therapy for IOP control, with few requiring more than 1 medication over the 26-week study. No eyes required surgical intervention for management of elevated IOP.1
Figure 1. A, Preimplant spectral-domain optical coherence tomographic (SD-OCT) scan (SPECTRALIS SD-OCT; Heidelberg Engineering, Carlsbad, California) of a macula in the left eye of a 41-year-old Hispanic woman with idiopathic, bilateral chronic iridocyclitis with multifocal choroiditis and cystoid macular edema. B, Preimplant SD-OCT scan of a macula in the right eye of the same woman. BM indicates Bruch's membrane; ILM, internal limiting membrane.
Figure 2. A, One-week postimplant spectral-domain optical coherence tomographic (SD-OCT) scan (SPECTRALIS SD-OCT; Heidelberg Engineering, Carlsbad, California) of a macula in the left eye of the same woman as inFigure 1. B, Two-week postimplant SD-OCT scan of a macula in the right eye of the same woman.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.